OPKO Health to Participate at Three Investment Conferences in December
November 30 2016 - 8:00AM
OPKO Health, Inc. (NASDAQ:OPK), announces that its
senior management team will host one-on-one investor meetings with
institutional investors participating at the following investor
conferences in December:
- Evercore ISI MedTools Investor Conference
taking place November 30-December 1, 2016 at the Boston Harbor
Hotel;
- Citi 2016 Global Healthcare Conference taking
place December 7-8, 2016 at the Lott New York Palace in New York
City;
- Guggenheim Securities 4th Annual Boston Healthcare
Conference taking place on December 13, 2016 at The
InterContinental Boston.
Attendance at these conferences is by invitation only. The
investor presentation used at the conferences will be posted to the
Investor Relations page of the Company's website at www.opko.com
under “Events” on the day of the event.
Institutional investors attending these conferences who are
interested in meeting with OPKO Health management should contact
their representatives at Evercore ISI, Citi and/or Guggenheim
Securities, respectively.
About OPKO Health, Inc.
OPKO Health is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing
markets. Our diagnostics business includes Bio-Reference
Laboratories, the nation's third-largest clinical laboratory with a
core genetic testing business and a 420-person sales force to drive
growth and leverage new products, including the 4Kscore® prostate
cancer test and the Claros® 1 in-office immunoassay platform. Our
pharmaceutical business features RAYALDEE, an FDA-approved
treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency, VARUBI™ for chemotherapy-induced nausea and vomiting
(oral formulation launched by partner TESARO and IV formulation
PDUFA date: January 2017), TT401, a once or twice weekly
oxyntomodulin for type 2 diabetes and obesity which is a clinically
advanced drug candidate among the new class of GLP-1 glucagon
receptor dual agonists, and TT701, an androgen receptor modulator
for androgen deficiency indications. Our biologics business
includes hGH-CTP, a once-weekly human growth hormone injection (in
phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug
for hemophilia (in phase 2a) and a long-acting oxyntomodulin for
diabetes and obesity (in phase 1). We also have production and
distribution assets worldwide, multiple strategic investments and
an active business development strategy. More information is
available at www.opko.com.
Company
OPKO Health, Inc.
Tara Mackay, 305-575-4100
Investor Relations
or
Media
Rooney & Associates
Terry Rooney, 212-223-0689
trooney@rooneyco.com
or
Marion Janic, 212-223-4017
mjanic@rooneyco.com
or
Investors
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024